Purpose-led, performance-driven

DSM, part of dsm-firmenich, is a global, purpose-led company in health and nutrition, applying science to improve the health of people, animals, and the planet. DSM’s purpose is to create brighter lives for all which we achieve through developing products and solutions that address some of the world’s biggest challenges while simultaneously creating economic, environmental, and societal value for all its stakeholders – customers, employees, shareholders, and society-at-large.

DSM at a glance

Key facts and figures about DSM, our broad, global health and nutrition business, and our people, planet and profit performance.
 

Results center

We routinely publish our financial performance, with more detail at half and full year where we also provide updates on key milestones on our strategic journey.

Share center

DSM has celebrated more than three decades since its privatisation and our ordinary shares being listed on the Euronext Stock Exchange in Amsterdam, the Netherlands.

Headlines (continuing operations) 2022

€8,390m

Net sales

€7,269m in 2021

€1,395m

Adjusted EBITDA

€1,379m in 2021

16.6%

Adjusted EBITDA margin

19.0% in 2021

Health, Nutrition & Bioscience

 

DSM’s continuing operations are organized around three business groups, each with clear opportunities to benefit the health of people and the health of the planet which underpin DSM’s growth plans.

Food & Beverage (F&B) combines food, beverage, and pet food activities. This business group is uniquely able to meet the needs of customers and consumers by developing sustainable taste, texture, and health solutions. The business group’s portfolio includes breakthrough innovations such as EVERSWEET™, a natural calorie-free sweetener, and CanolaPRO®, a plant-based alternative protein.

Health, Nutrition & Care (HNC) aims to keep the world’s growing population healthy through nutrition and care. This business group provides unique, sustainable, science-based and innovative solutions for consumers in early-life nutrition, dietary supplements, pharma, medical nutrition, personal care, fragrances, and biomedical materials, as well as nutrition improvement for the most vulnerable communities. It includes a rich innovation portfolio including ampli-D®, the rapid-acting and potent form of vitamin D, an extensive algal lipids portfolio, personalized nutrition initiatives such as Hologram Sciences™, as well as human milk oligosaccharide-prebiotics.

Animal Nutrition & Health (ANH) focuses on specialty solutions for a radical transformation in the sustainability of animal protein production. Incorporating essential products such as vitamins, carotenoids, eubiotics and mycotoxin risk management, as well as a wide range of impactful innovations such as methane inhibitor Bovaer® and fish-oil algae-alternative Veramaris®. This business group also includes precision initiatives with data-driven decision-making tools for famers like Sustell™, and for veterinarians and animal health practitioners like Verax™.

€8,319m

Net Sales

€1,490m

Adjusted EBITDA

17.9%

Adjusted EBITDA margin

€3,788m

Animal Nutrition & Health

€2,939m

Health Nutrition & Care

€1,546m

Food & Beverage

Latest financial & regulatory news

  • DSM - delivery of shares

    28 Apr 2023

    Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

  • DSM - delivery of shares

    26 Apr 2023

    Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

Read more

  • DSM at a glance

    DSM at a glance

    Key facts and figures about DSM, our business and our people, planet & profit performance in one overview.

  • Financial results & presentations

    Financial results & presentations

    Instant overview of the financial results, presentations, updates & AGMs and all DSM's financial and regulatory press releases from the last decade.